1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$85.67bn
- HK$90.92bn
- CNY31.83bn
Sino Biopharmaceutical hits almost 4-year peak on plan to buy out LaNova
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Brief: Sino Biopharmaceutical Fully Buys Lanova Medicines
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million (updated)
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
Brief: Sino Biopharmaceutical Updates On Culmerciclib Capsule
Brief: Sino Biopharmaceutical Says Recombinant Human Coagulation Factor Viia N01 Approved By NMPA
Brief: Sino Biopharmaceutical Says LM-108 Included In Breakthrough Therapy Designation
Brief: Sino Biopharmaceutical Says New Indication Of TDI01 Suspension ("Rock2 Inhibitor") Included In Breakthrough Therapy Designation Process By CDE
Brief: Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection
Brief: Sino Biopharmaceutical Says Tqc3721 Inhalation Suspension Approved By Center For Drug Evaluation
Brief: Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA
Brief: Sino Biopharmaceutical Says Positive Results On Phase 3 Study Of Culmerciclib In Combination With Fulvestrant
Brief: Sino Biopharmaceutical Recommends Payment Of Final Dividend Of HK4 Cents Per Share
Brief: Sino Biopharmaceutical Enters Exclusive Cooperation Agreement With Delova Biotech For QP001
Brief: Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences
Hong Kong stocks close firmer as Lunar New Year holiday kicks in
Brief: Sino Biopharmaceutical Says Positive Results From Phase III Study Of Benmelstobart Injection